Opinion|Videos|January 13, 2025
Emerging Therapies: a look at the current data: ALIGN
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how the ALIGN trial data inform the development and potential impact of emerging therapies for IgA nephropathy, particularly focusing on their efficacy in reducing proteinuria and addressing disease pathology.
Advertisement
Episodes in this series
- In the phase 3 ALIGN trial (
NCT04573478 ), atrasentan demonstrated a 36% relative reduction in proteinuria with placebo after 36 weeks of treatment. What other data points would be relevant for clinicians?
Advertisement
Related to this article
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use
2
Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD
3
Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes
4
Why Clinicians Should Not Wait to Augment Inadequate Response in MDD
5